General Assembly – Uppsala, Sweden

July 13, 2016
No Comments

The 4th PreDiCT-TB General Assembly meeting took place at Uppsala Universitet, Uppsala, Sweden on 11th/12th May 2016  and was attended by 66 people from eight countries

Phase III Studies

April 20, 2016
No Comments

CPATH have now made the phase III studies including REMoxTB available to the TB community. Further information can be found here: https://c-path.org/programs/tb-pacts http://www.tballiance.org/news/new-tb-clinical-trial-data-sharing-platform-available-researchers http://medicine.st-andrews.ac.uk/blog/accelerating-tb-research

World TB Day – St. Andrews Public Engagement

March 24, 2016
No Comments

The research team at St Andrews has developed a new computerized automated simulation model to study tuberculosis disease progression and treatment in the lung. This model plots how the bugs that cause disease …

World TB Day – Video from the Madrid Group

March 24, 2016
No Comments

This piece is from our PreDiCT-TB colleagues at Universidad Carlos III in Madrid showing their state-of-the-art X-ray CT technique that automatically quantifies the bacterial load in TB patient’s lungs.

World TB Day – Uppsala University

March 23, 2016
No Comments

Uppsala – the city of science. Founded in 1477, Uppsala University is the oldest University in Sweden and home to a thriving Faculty of Pharmacy situated at the Biomedical Center. The pharmacometrics research …

2016 Meetings

February 5, 2016
No Comments

The following key meetings will take place during 2016.  Please click on the meeting for further information. June 21st – 23rd 2016:  London, UK – The 2016 TB Summit. 24th October 2016: Liverpool, …

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.